N-Terminal Pro-Brain Type Natriuretic Peptide
NT PRO BNP
Description
N-Terminal Pro-Brain Type Natriuretic Peptide (NT-proBNP) test checks the level of NT-proBNP, a hormone your heart releases when it’s under pressure or working harder than usual. Doctors often use this test to diagnose or monitor heart failure, as high levels can mean your heart isn’t pumping as well as it should. A blood sample is tested, and elevated levels may point to heart strain, while normal levels usually suggest your heart is functioning well. This test is especially helpful for people with symptoms like shortness of breath, fatigue, or swelling. The results help doctors understand your heart’s condition and decide on treatments, such as medications, lifestyle adjustments, or further tests. Regular NT-proBNP testing can help track your heart health and stay on top of your cardiac health.
Procedure
Invasive
Sample Type
Blood – Serum
Test Category
Proteins
Procedure Category
Blood Draw
Units
Picograms Per Milliliter
Test Groups
Basic Cardiovascular Group: This group includes fundamental tests targeting essential markers related to cardiovascular health, providing foundational insights into cholesterol levels, blood pressure, and other key factors. Complete Cardiovascular Group: This group contains comprehensive tests for an extensive evaluation of cardiovascular health, providing thorough insights into heart-related conditions beyond basic assessments. Complete Pulmonary Function Group: Comprehensive evaluations of respiratory function offer detailed insights into lung function, airway inflammation, and structural abnormalities, facilitating the precise diagnosis and management of pulmonary conditions. Proteins Group: This group comprises tests assessing various aspects of protein levels and function, providing valuable insights into overall protein status and associated health considerations.
Optimal Range
For All Individuals:
Conventional Unit: < 125.00 pg/mL
SI Unit: Not Applicable
Normal Range
Ages 0–75 Years:
Conventional Unit: < 125.00 pg/mL
SI Unit: Not Applicable
Ages 75+ Years:
Conventional Unit: < 450.00 pg/mL
SI Unit: Not Applicable
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Atrial fibrillation (Irregular heartbeat that can lead to heart-related complications)
Chronic obstructive pulmonary disease (lung condition that obstructs airflow)
Coronary artery disease (Narrowing of the coronary arteries leading to reduced blood flow to the heart)
Heart failure (Inability of the heart to pump blood effectively)
- ...
Key Reasons For Testing
Cardiac Function Assessment: Evaluates heart function, particularly in diagnosing and monitoring heart failure.
Heart Failure Diagnosis: Identifies myocardial strain and distinguishes heart failure from other causes of dyspnea.
Prognostic Indicator: Predicts outcomes and severity in heart failure patients.
Risk Stratification: Assesses cardiovascular event risks in individuals with heart disease.
Monitoring Treatment Response: Tracks therapy effectiveness in heart failure management.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Corteville DC, Bibbins-Domingo K, Wu AH, Ali S, Schiller NB, Whooley MA. N-terminal pro-B-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with coronary disease: data from the Heart and Soul Study. Arch Intern Med. 2007;167(5):483-489.
[2] Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am J Cardiol. 2005;95(8):948-954.
[3] Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357-2368.
[4] Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350(7):647-654.
[5] Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97(19):1921-1929.
[6] Ibrahim NE, McCarthy CP, Shrestha S, et al. Established and emerging roles of biomarkers in heart failure clinical trials. Circ Heart Fail. 2016;9(5).
[7] Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52(12):997-1003.
[8] Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006;151(5):999-1005.
[9] Lainchbury JG, Troughton RW, Strangman KM, et al. NT-proBNP-guided treatment for chronic heart failure: Results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55(1):53-60.
[10] Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350(9088):1349-1353.
[11] Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, et al. Comparison of BNP and NT-proBNP in diagnosing heart failure in patients with preserved systolic function. Eur J Heart Fail. 2004;6(6):804-809.
[12] McDonagh TA, Holmer S, Raymond I, et al. NT-proBNP and the diagnosis of heart failure: A pooled analysis of three studies. Eur J Heart Fail. 2004;6(3):269-273.
[13] Berger R, Moertl D, Peter S, et al. N-terminal pro-brain natriuretic peptide-guided heart failure therapy reduces the incidence of sudden cardiac death. Eur J Heart Fail. 2010;12(9):901-908.
[14] Groenning BA, Nilsson JC, Sondergaard L, et al. Plasma N-terminal pro-brain natriuretic peptide and long-term mortality in patients with heart failure and preserved systolic function. Circulation. 2002;105(15):1768-1773.